The size and number of Phase I oncology trials is increasing fast – but with treatment advances come new challenges. To optimise study outcomes, better cooperation is needed between regional staff, and decisions should be informed by experts in the field.

[embeddoc url=”https://www.vectoroncology.com/articles/92014EPCpp26-27.pdf” viewer=”google”]

2017-07-03T20:49:29+00:00 August 26th, 2014|